Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research,…

Read MoreWellbeing Digital Enters into Share Purchase Agreement with Cardinal Group

Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study

A pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces promising preliminary results from its Proof of Concept (POC) Phase 2a clinical trial…

Read MoreSensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study

Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products

A clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 5,500 square meter (60,000 square feet) Vaxxas Biomedical Facility will serve as the company’s global…

Read MoreVaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products

Global Life Science Instrumentation Market Report 2023: Sector is Expected to Reach $107.3 Billion by 2030 at a CAGR of 6.5% – ResearchAndMarkets.com

The global life science instrumentation market size was valued at USD 68336.6 million in 2021 and is poised to grow from USD 72858.98 million in 2022 to USD 107344.2 million by 2030, growing at a CAGR of 6.5% in the…

Read MoreGlobal Life Science Instrumentation Market Report 2023: Sector is Expected to Reach $107.3 Billion by 2030 at a CAGR of 6.5% – ResearchAndMarkets.com

International Niemann-Pick Disease Registry and Mandos Health announce new research collaboration using real-world data to evaluate the treatment effects of VTS-270 to manage Niemann-Pick type C1

The International Niemann-Pick Disease Registry (INPDR) and biopharmaceutical company Mandos Health today announce a new collaboration giving Mandos Health controlled access to registry information via INPDR’s research “Gateway” platform. This partnership will provide Mandos Health with real-world evidence that will…

Read MoreInternational Niemann-Pick Disease Registry and Mandos Health announce new research collaboration using real-world data to evaluate the treatment effects of VTS-270 to manage Niemann-Pick type C1

Trilliant Health’s 2023 SimilarityIndex™ | Hospitals Reveals Wide Variation in Commercial Reimbursement Despite Similar Quality and Patient Acuity

Trilliant Health, the healthcare industry’s leading predictive analytics and market research firm, today released the 2023 SimilarityIndex™ | Hospitals, the health economy’s only data-driven hospital benchmarking analysis. SimilarityIndex™ | Hospitals uses machine learning models to identify the 50 most similar peer…

Read MoreTrilliant Health’s 2023 SimilarityIndex™ | Hospitals Reveals Wide Variation in Commercial Reimbursement Despite Similar Quality and Patient Acuity

Podimetrics Expands Leadership Team with Addition of Chief Commercial Officer, Barbara Greising

Podimetrics, creator of the SmartMat™ and integrated clinical and patient support services that can help save the limbs and lives of people living with complex diabetes, today announced Barbara Greising will be joining the Podimetrics executive leadership team as Chief Commercial Officer.…

Read MorePodimetrics Expands Leadership Team with Addition of Chief Commercial Officer, Barbara Greising

Sojitz Signs Memorandum of Understanding for Strategic Alliance with HIROTSU Bioscience,WHO FOUNDATION, OurCrowd and GLOBAL HEALTH Equity Fund

TheSojitz Corporation (“Sojitz”) has signed a memorandum of understanding with HIROTSU Bioscience Inc. (“HIROTSU”), a developer and provider of N-NOSE®, a primary cancer screening test offering early cancer detection, the WHO Foundation (“WHO Foundation”), OurCrowd, a venture capital firm and the Global Health Equity Fund (“GHEF”), a fund…

Read MoreSojitz Signs Memorandum of Understanding for Strategic Alliance with HIROTSU Bioscience,WHO FOUNDATION, OurCrowd and GLOBAL HEALTH Equity Fund

Labcorp Announces Launch of Fortrea’s Notes Offering in Connection with Anticipated Spinoff

A leading global life sciences company, today announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp (“Fortrea”), has launched an offering of senior secured notes due 2030 (the “Notes”), subject to market conditions and other customary factors, in connection with the…

Read MoreLabcorp Announces Launch of Fortrea’s Notes Offering in Connection with Anticipated Spinoff